Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

NCT02535338 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

11

Enrollment

NIH

Sponsor class

Conditions

Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions

DRUG: Erlotinib Hydrochloride
OTHER: Laboratory Biomarker Analysis
DRUG: Onalespib Lactate
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)